Top-Rated StocksTop-RatedNYSE:IQV IQVIA (IQV) Stock Price, News & Analysis $171.47 -1.71 (-0.99%) Closing price 03:59 PM EasternExtended Trading$169.28 -2.19 (-1.28%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IQVIA Stock (NYSE:IQV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IQVIA alerts:Sign Up Key Stats Today's Range$165.44▼$171.9750-Day Range$156.42▼$178.9552-Week Range$134.65▼$247.04Volume2.16 million shsAverage Volume1.76 million shsMarket Capitalization$28.62 billionP/E Ratio21.25Dividend YieldN/APrice Target$225.69Consensus RatingBuy Company Overview IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets. IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management. The company maintains proprietary healthcare and commercial data assets and deploys analytics and machine learning to help clients identify patient populations, optimize trial design and accelerate product commercialization. In addition to trial execution, IQVIA offers consulting and commercialization services that support market access, medical affairs and performance improvement across product lifecycles. Operating globally, IQVIA serves pharmaceutical and biotechnology companies, medical device manufacturers, payers, providers and government agencies across more than 100 countries. Its combination of clinical services, data resources and software platforms positions the company to support customers from early development through post‑market evidence generation and commercial operations. Because leadership and operational details can change, readers should consult the company’s filings and corporate communications for the latest governance information.AI Generated. May Contain Errors. Read More IQVIA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreIQV MarketRank™: IQVIA scored higher than 82% of companies evaluated by MarketBeat, and ranked 87th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingIQVIA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 13 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialIQVIA has a consensus price target of $225.69, representing about 31.6% upside from its current price of $171.47.Amount of Analyst CoverageIQVIA has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IQVIA's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth11.67% Earnings GrowthEarnings for IQVIA are expected to grow by 11.67% in the coming year, from $11.57 to $12.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IQVIA is 21.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of IQVIA is 21.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.73.Price to Earnings Growth RatioIQVIA has a PEG Ratio of 1.65. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIQVIA has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IQVIA's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.02% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 3.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently increased by 3.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIQVIA does not currently pay a dividend.Dividend GrowthIQVIA does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.17 News SentimentIQVIA has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IQVIA this week, compared to 7 articles on an average week.Search Interest14 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows4 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IQVIA insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of IQVIA is held by insiders.Percentage Held by Institutions89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IQVIA's insider trading history. Receive IQV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IQV Stock News HeadlinesIQVIA: The Market May Be Missing The AI And Data Story32 minutes ago | seekingalpha.comIQVIA Holdings Inc QTSMay 19 at 10:27 PM | morningstar.comMAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $500 into a fortune while the average stock lost 90% of its value. His son Martin later digitized those same formulas into Weiss Ratings, a system now tracking 22,000 stocks with 1.2 billion daily calculations. That system called the bank failures of the 1980s, the dot-com bust, 2008, and the 2020 crash. Right now it is flashing Code Red - issuing Must-Sell warnings on 10 widely held US stocks and upgrading 3 under-the-radar names to an urgent Buy. Access the full briefing at 79% off during the Memorial Day Savings Event.May 20 at 1:00 AM | Weiss Ratings (Ad)Artisan Select Equity Fund Q1 2026 CommentaryMay 19 at 10:27 PM | seekingalpha.comIQVIA’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 16, 2026 | finance.yahoo.comWill IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative?May 16, 2026 | finance.yahoo.comIQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Recommendation of "Buy" from BrokeragesMay 16, 2026 | americanbankingnews.comWhat to Know About the New Obsession With TestosteroneMay 13, 2026 | nytimes.comSee More Headlines IQV Stock Analysis - Frequently Asked Questions How have IQV shares performed this year? IQVIA's stock was trading at $225.40 at the beginning of 2026. Since then, IQV shares have decreased by 23.9% and is now trading at $171.4680. How were IQVIA's earnings last quarter? IQVIA Holdings Inc. (NYSE:IQV) released its earnings results on Tuesday, May, 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.83 by $0.07. The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. Read the conference call transcript. Is IQVIA buying back stock? IQVIA's Board of Directors approved a share buyback plan on Thursday, May 7th 2026, which authorizes the company to buy back $2,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its stock is undervalued. Does IQVIA have any subsidiaries? The following companies are subsidiaries of IQVIA: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more. When did IQVIA IPO? IQVIA (IQV) raised $900 million in an initial public offering (IPO) on Thursday, May 9th 2013. The company issued 23,684,210 shares at a price of $36.00-$40.00 per share. Who are IQVIA's major shareholders? IQVIA's top institutional shareholders include Lazard Asset Management LLC (1.11%), Cantillon Capital Management LLC (1.01%), Dimensional Fund Advisors LP (0.98%) and Bank of America Corp DE (0.78%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly, Keriann Cherofsky and John G Danhakl. View institutional ownership trends. How do I buy shares of IQVIA? Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IQVIA own? Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK). Company Calendar Last Earnings5/05/2026Today5/20/2026Next Earnings (Estimated)7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IQV's financial health is in the Red zone, according to TradeSmith. IQV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryBusiness Services Current SymbolNYSE:IQV CIK1478242 Webwww.iqvia.com Phone(919) 998-2000FaxN/AEmployees93,000Year Founded2016Price Target and Rating Average Price Target for IQVIA$225.69 High Price Target$258.00 Low Price Target$185.00 Potential Upside/Downside+31.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$8.07 Trailing P/E Ratio21.25 Forward P/E Ratio14.82 P/E Growth1.66Net Income$1.36 billion Net Margins8.33% Pretax Margin9.60% Return on Equity30.50% Return on Assets6.53% Debt Debt-to-Equity Ratio2.20 Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual Sales$16.31 billion Price / Sales1.75 Cash Flow$17.70 per share Price / Cash Flow9.69 Book Value$38.04 per share Price / Book4.51Miscellaneous Outstanding Shares166,900,000Free Float164,063,000Market Cap$28.62 billion OptionableOptionable Beta1.18 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:IQV) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
